← Back to Search

Chatbot Monitoring for Lung Cancer Medication Adherence (iSMART Trial)

N/A
Waitlist Available
Led By Samuel U Takvorian, MD, MSHP
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult patient (age > 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks after study initiation or at therapy discontinuation, whichever is shorter
Awards & highlights

iSMART Trial Summary

This trial will test a new conversational agent to help manage side effects and improve adherence to oral targeted therapies for lung cancer patients.

Who is the study for?
This trial is for adults over 18 with non-small cell lung cancer (NSCLC) at UPHS who are taking specific oral therapies and own a mobile device that can text. They must be able to interact in English and have their oncologist's approval to participate, but cannot be in another therapeutic clinical trial or taking multiple oral therapies.Check my eligibility
What is being tested?
The study compares usual care against the use of a conversational agent/chatbot named 'Penny' designed to help patients manage side effects and stick to their medication schedule. It's a two-arm randomized controlled trial where participants will either continue with their regular care or engage with 'Penny'.See study design
What are the potential side effects?
Since this trial focuses on adherence strategies rather than new medications, there aren't direct side effects from interventions being tested. However, managing existing side effects of the listed oral therapies effectively is part of what's being studied.

iSMART Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 with NSCLC and am taking a specific oral cancer medication.

iSMART Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after study initiation or at therapy discontinuation, whichever is shorter
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks after study initiation or at therapy discontinuation, whichever is shorter for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adherence
Secondary outcome measures
Persistence

iSMART Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment1 Intervention
Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
Group II: Control ArmActive Control1 Intervention
Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,880,013 Total Patients Enrolled
PfizerIndustry Sponsor
4,567 Previous Clinical Trials
10,911,799 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
145,620 Total Patients Enrolled

Media Library

Conversational Agent/Chatbot Clinical Trial Eligibility Overview. Trial Name: NCT04347161 — N/A
Lung Cancer Research Study Groups: Intervention Arm, Control Arm
Lung Cancer Clinical Trial 2023: Conversational Agent/Chatbot Highlights & Side Effects. Trial Name: NCT04347161 — N/A
Conversational Agent/Chatbot 2023 Treatment Timeline for Medical Study. Trial Name: NCT04347161 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still open for this clinical trial?

"Clinicaltrials.gov does not list this particular trial as actively recruiting at the moment, despite its initial posting date of February 22nd 2021 and most recent edit on October 12th 2022. Nevertheless, there are 1724 other medical trials globally currently in need of patient participation."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Implementation Strategies for Monitoring Adherence in Real Time
Katharine Rendle 2021. "Implementation Strategies for Monitoring Adherence in Real Time". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04347161.
All > Lung Cancer Baltimore
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top